Liquidia Corporation (LQDA) Exceeds Expectations for Q4 Earnings and Revenue

Liquidia Corporation Reports Strong Quarterly Results

Liquidia Corporation (LQDA) posted adjusted earnings of $0.15 per share for the recent quarter, significantly exceeding the Zacks Consensus Estimate of $0.08 per share. In comparison, the company reported a loss of $0.46 per share during the same period last year. These results exclude one-time items.

This performance marks a 100% positive earnings surprise. In the previous quarter, analysts had anticipated a loss of $0.45 per share, but the actual loss was only $0.04, resulting in a 91.11% surprise. Over the past year, Liquidia has outperformed consensus earnings per share estimates in two out of four quarters.

For the quarter ending December 2025, Liquidia, a member of the Zacks Medical - Biomedical and Genetics sector, generated $92.02 million in revenue, beating expectations by 19.34%. This is a substantial increase from $2.92 million in revenue a year earlier. The company has surpassed revenue forecasts three times in the last four quarters.

The immediate impact of these results on the stock price will largely depend on management's insights shared during the earnings call and future guidance.

Since the start of the year, Liquidia shares have dipped by approximately 0.3%, while the S&P 500 has gained 0.4% in the same period.

What Lies Ahead for Liquidia Corporation?

Although Liquidia Corporation has lagged behind the broader market so far this year, investors are now wondering about the company's future prospects.

One of the most reliable ways to gauge a stock's potential is by examining its earnings outlook, which includes both current consensus estimates and recent changes to those forecasts.

Research consistently shows that short-term stock price movements are closely linked to trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools such as the Zacks Rank, which has a strong record of leveraging earnings estimate trends.

Before this earnings announcement, analyst revisions for Liquidia were mixed. While the latest results may influence future estimate changes, the current outlook gives the stock a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market.

It will be important to watch how analyst estimates for upcoming quarters and the current fiscal year evolve. Presently, the consensus expects earnings per share of $0.20 on $79.43 million in revenue for the next quarter, and $1.05 per share on $368.29 million in revenue for the full year.

Investors should also consider the broader industry outlook, as it can significantly affect stock performance. The Medical - Biomedical and Genetics industry currently ranks in the lower 46% of over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperforms the bottom half by more than two to one.

Industry Comparison: Codexis (CDXS)

Another company in the same sector, Codexis (CDXS), has not yet released its results for the quarter ending December 2025, with the report expected on March 11.

Codexis, which specializes in custom industrial enzymes, is projected to report quarterly earnings of $0.01 per share, representing a 107.7% year-over-year improvement. The consensus EPS estimate for this period has remained steady over the past month.

Revenue for Codexis is anticipated to reach $38.3 million, up 78.5% from the same quarter last year.

Is Liquidia Corporation (LQDA) a Good Investment?

Thinking about investing in Liquidia Corporation (LQDA)?

Since 1978, Zacks Investment Research has provided investors with independent research and analytical tools. Over the past 25+ years, the Zacks Rank stock-rating system has delivered an average annual return of +24.08%, more than doubling the S&P 500 (measured from January 1, 1988 to May 6, 2024).